Combined BRAF and MEK inhibition in BRAF-mutant NSCLC.
Department of Medical Oncology, Austin Health, Olivia Newton- John Cancer and Wellness Centre, VIC 3084, Australia; University of Melbourne, VIC, Australia.
Gareth
G
Rivalland
Department of Medical Oncology, Austin Health, Olivia Newton- John Cancer and Wellness Centre, VIC 3084, Australia; University of Melbourne, VIC, Australia; Thoracic Alliance for Cancer Trials, Milton, QLD, Australia. Electronic address: paul.mitchell@austin.org.au.
Paul
P
Mitchell
D002289:Carcinoma, Non-Small-Cell Lung; D045744:Cell Line, Tumor; D006801:Humans; D008175:Lung Neoplasms; D008545:Melanoma; D009154:Mutation; D047428:Protein Kinase Inhibitors; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*
D047428:Protein Kinase Inhibitors; D048493:Proto-Oncogene Proteins B-raf